ExxonMobil and the government of Guyana are discussing which unexplored offshore blocks the U.S. supermajor should return to the country under its 2016 exploration and production contract.
Energy Regulator Claims Canadian Oil Production Will Plunge 76% By 2050Oil Prices Flat Ahead Of Powell's Brief To Congress2023 Biodiesel Quotas Disappoint U.S.
ProducersChina Extends EV Subsidies To Reverse Flagging SalesFuture Of Ecuadorian Oil At Stake As Country Votes For New PresidentCentral And Eastern Europe Seeks Balance In Ukrainian Grain TradeGerman Carmakers To Suffer As China’s EV Boom AcceleratesIndonesia To Stop Exports Of Copper Concentrates In 2024Civitas Resources Plans $5 Billion Expansion In The PermianKhartoum Crisis Could Hold South Sudan Oil HostageRussia’s Crude Oil Processing Hits New HighsBlinken And Xi Sit Down In “Positive...
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Interview: Toys For Bob on Crash Team Rumble, Call of Duty and the future | VGCInterview: We spoke to ToysForBob about today's Crash Team Rumble launch, its experience working on Call of Duty, and the future.
Read more »
Ministers to block plans to ban new coal minesMeasures to allow community projects to sell electricity directly to local homes are also set to be dropped.
Read more »
Future Of Ecuadorian Oil At Stake As Country Votes For New President | OilPrice.comEcuador could lose $1.2 billion in annual oil income should a vote to stop production in a major oil block prove successful, the country's energy ministry said on Tuesday.
Read more »
Hospital alternative campaigns 'not over' amid 'inequalities' fearsCampaigners have warned a 16-storey tower block hospital in the middle of Watford will not solve West Herts’ health needs.
Read more »
Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial - BMC Infectious DiseasesBackground Shortly after the Coronavirus disease 2019 (COVID-19) pandemic, a considerable number of recovered patients reported persisting symptoms, especially neuropsychological manifestations, which were later named post-COVID syndrome (PCS). Immune dysregulation was suggested as one of the main mechanisms for PCS. Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that is mostly used to treat depression, anxiety disorders, and obsessive–compulsive disorder, has been suggested as an anti-COVID drug due to its anti-inflammatory effects, mainly through the sigma-1 receptor. Therefore, we aimed to evaluate fluvoxamine's effect on PCS neuropsychiatric symptoms. Method In this double-blind randomized clinical trial, we included confirmed mild to moderate COVID-19 outpatients using polymerase chain reaction (PCR) by an infectious disease specialist. The presence of severe COVID-19 symptoms was evaluated by the infectious disease specialist and included dyspnea, SpO2 30 breaths/min, and lung infiltrates | 50%. Then we performed permuted block randomization and assigned patients 1:1 into two groups to either receive fluvoxamine 100 mg tablet or a placebo daily for 10 days. Eligible patients were evaluated after 12 weeks for the presence of fatigue, as the primary, and other PCS symptoms as secondary outcomes. Results We screened a total of 486 patients from March to June 2022. After 12 weeks, 42 patients receiving fluvoxamine and 43 patients receiving Placebo were evaluated for PCS. Patients had a mean age of 38.5 ± 14.1 and 48% of them were women. Fatigue was significantly lower in the fluvoxamine group (p-value 0.026). No significant differences were observed in other symptoms. Conclusion We concluded that taking fluvoxamine during active COVID-19 can reduce the chance of fatigue but the advantage of fluvoxamine was not observed for other symptoms. Further studies are necessary to confirm these preliminary results.
Read more »